Holen Sie sich die Stockscreener-App
255.56
0.90%
2.28
Handel nachbörslich:
255.00
-0.56
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Johnson Johnson Aktie (JNJ) Neueste Nachrichten
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool
Breakfast News: Week in Review - The Motley Fool
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
3 Companies Raising Guidance This Earnings Season - Zacks Investment Research
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView
The Open Question Under Johnson & Johnson Stock’s Price - Trefis
Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St.
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges - Zacks Investment Research
Johnson & Johnson Reports Q3 2026 Results, Raises Full-Year Guidance - VisionMonday.com
Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint - MassDevice
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
Johnson & Johnson: Keep Calm And Hold On (NYSE:JNJ) - Seeking Alpha
J&J’s medtech business slows again in Q3 - MedTech Dive
Johnson & Johnson shares fall following earnings - CNBC
Why Johnson & Johnson Stock Dropped Today - The Motley Fool
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth - Morningstar
Why Johnson & Johnson Stock Dropped Today - Yahoo Finance
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance
Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading - The Motley Fool
What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call - Yahoo Finance
J&J’s new pharma chief expects Icotyde’s psoriasis launch momentum to repeat across indications - Fierce Pharma
Small-Business Optimism Dips in September - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Mixed Pre-Markets Greet Fresh Q3 Earnings Reports - Zacks Investment Research
Johnson & Johnson (JNJ) Reports 5.9% Revenue Growth, Plans Busin - GuruFocus
Johnson & Johnson (JNJ) Q3 FY2026 earnings call transcript - Yahoo Finance
Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After Q3 Beat - GuruFocus
J&J's Tremfya posts forecast-topping quarter - FirstWord Pharma
Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock Drops - RTTNews
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 - BioSpace
Johnson & Johnson CFO Joseph Wolk on the company’s Q3 results - CNBC
Johnson & Johnson raises profit guidance in Q3 2026 earnings - Quartz
JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings - Quiver Quantitative
J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Reuters
J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027 - CNBC
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Yahoo Finance
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Zacks Investment Research
Johnson and Johnson Earnings Report | 2026 Q3 Infographic - Johnson & Johnson
J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business - WSJ
J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Yahoo Finance
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance - Business Wire
Johnson & Johnson (JNJ) Stock May Be 28% Undervalued As TREMFYA Data Impresses - Yahoo Finance
Johnson & Johnson (JNJ) Stock May Be A Bargain Following New TREMFYA Trial Data - Simply Wall Street
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
0.71%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):